景峯醫藥(000908.SZ)子公司收到兩份藥品再註冊批件
格隆匯8月21日丨景峯醫藥(000908.SZ)公佈,公司全資子公司上海景峯製藥有限公司於近日收到上海市藥品監督管理局核准簽發的兩份《藥品再註冊批件》。
1、藥品通用名稱:玻璃酸鈉;劑型:原料藥;藥品分類:化學藥品;藥品批准文號有效期:2024年7月11日;藥品有效期:24個月;審批結論:經審查,本品符合《藥品註冊管理辦法》的有關規定,同意再註冊。
2、藥品通用名稱:玻璃酸鈉注射液;劑型:注射劑;規格:2.5ml:25mg;藥品分類:化學藥品;藥品批准文號有效期:2024年7月11日;藥品有效期:24個月;審批結論:經審查,本品符合《藥品註冊管理辦法》的有關規定,同意再註冊。
玻璃酸鈉注射液主要用於變形性膝關節病和肩關節周圍炎的輔助治療。
上述兩款藥品再註冊批件的獲得確保了公司玻璃酸鈉原料藥、玻璃酸鈉注射液的正常生產和銷售,對公司未來發展將產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.